Aptevo Therapeutics Inc.
Datakwaliteit: 83%
APVO
Nasdaq
Manufacturing
Chemicals
€ 4,37
▲
€ 0,09
(2,10%)
Marktkapitalisatie: 5,16 M
Prijs
€ 4,37
Marktkapitalisatie
5,16 M
Dagbereik
€ 4,25 — € 4,38
52-Weeksbereik
€ 3,80 — € 486,00
Volume
15.186
Openen € 4,35
50D / 200D Gem.
€ 6,06
27,90% below
50D / 200D Gem.
€ 25,19
82,65% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -25,59 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-217,15%
Onder sectorgemiddelde (-53,41%)
ROIC-129,45%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio4,03
Interest CoverageN/A
Waardering
PE (TTM)
-0,20
Boven sectorgemiddelde (-1,48)
P/B Ratio0,30
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,2 | -1,5 |
| P/B | 0,3 | 1,6 |
| ROE % | -217,2 | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -25,97 M |
| ROE | -217,15% | ROA | -121,85% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -25,59 M |
| ROIC | -129,45% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 4,03 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 17,04 M | Tangible Book Value | 17,39 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,20 | Forward P/E | N/A |
| P/B Ratio | 0,30 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -495,57% | ||
| Market Cap | 5,16 M | Enterprise Value | -15,90 M |
| Per Share | |||
| EPS (Diluted TTM) | -87,27 | Revenue / Share | N/A |
| FCF / Share | -21,66 | OCF / Share | -21,66 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 98,56% |
| SBC-Adj. FCF | -25,84 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | 3,11 M | 3,11 M | 12,29 M |
| Net Income | -25,97 M | -24,13 M | -17,41 M | 8,03 M | -28,46 M |
| EPS (Diluted) | -87,27 | -87,38 | -1,42 | 1,57 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -26,31 M | -24,60 M | -28,88 M | -28,64 M | -21,40 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 14,54 M | 14,38 M | 17,11 M | 17,88 M | 18,99 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 240.000,0 | 352.000,0 | 567.000,0 | 901.000,0 | 1,14 M |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0,0 | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 27,19 M | 15,59 M | 24,84 M | 34,22 M | 56,60 M |
| Total Liabilities | 9,81 M | 10,84 M | 12,62 M | 16,24 M | 55,39 M |
| Shareholders' Equity | 17,38 M | 4,76 M | 12,22 M | 17,97 M | 1,22 M |
| Total Debt | — | — | 0,0 | 4,01 M | 16,02 M |
| Cash & Equivalents | 21,62 M | 8,71 M | 16,90 M | 22,64 M | 45,04 M |
| Current Assets | 23,08 M | 10,66 M | 19,07 M | 27,45 M | 52,57 M |
| Current Liabilities | 6,05 M | 6,21 M | 7,22 M | 8,71 M | 34,76 M |
{"event":"ticker_viewed","properties":{"ticker":"APVO","listing_kind":"stock","pathname":"/stocks/apvo","exchange":"Nasdaq","country":"US"}}